Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19

Azita H. Talasaz; Parham Sadeghipour; Maryam Aghakouchakzadeh; Isaac Dreyfus; Hessam Kakavand; Hamid Ariannejad; Aakriti Gupta; Mahesh V. Madhavan; Benjamín Van Tassell; David Jiménez; Manuel Monréal; Muthiah Vaduganathan; John Fanikos; Dave L. Dixon; Gregory Piazza; Sahil A. Parikh; Deepak L. Bhatt; Professor Gregory Lip; Gregg W. Stone; Harlan M. Krumholz; Peter Libby; Samuel Z. Goldhaber; Behnood Bikdeli

doi:10.1016/j.jacc.2021.08.021

Preprint2021

Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials

Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V. Madhavan, Benjamín W. Van Tassell, David González Jiménez, Manuel Monréal, Muthiah Vaduganathan, John Fanikos, Dave L. Dixon, Gregory Piazza, Sahil A. Parikh, Deepak L. Bhatt, Professor Gregory Lip, Gregg W. Stone, Harlan M. Krumholz, Peter Libby, Samuel Z. Goldhaber, Behnood Bikdeli

Article2022

Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19

Farhad Khimani, Adam J. Wolf, Braian Yoon, Amy Blancke, Coltin Gerhart, Dakota Endsley, Alleyna Dougherty, Anish Ray, Angelito F. Yango, Stuart D. Flynn, Professor Gregory Lip, Stevan A. Gonzalez, Mohanakrishnan Sathyamoorthy

Article2020

Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19

Sara Schumann, Astrid Kaiser, Ferdinando Nicoletti, Katia Mangano, Paolo Fagone, Eduard van Wijk, Yu Yan, Petra Schulz, Beate Ludescher, Michael Niedermaier, Joerg von Wegerer, Pia Rauch, Christian Setz, Ulrich Sigmar Schubert, Wolfgang Brysch

Preprint2020

Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19

Sara Schumann, Astrid Kaiser, Ferdinando Nicoletti, Katia Mangano, Paolo Fagone, Eduard van Wijk, Yu Yan, Petra Schulz, Beate Ludescher, Michael Niedermaier, Joerg von Wegerer, Pia Rauch, Christian Setz, Ulrich Sigmar Schubert, Wolfgang Brysch

Article2020

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Behnood Bikdeli, Mahesh V. Madhavan, David Jiménez, Taylor Chuich, Isaac Dreyfus, Elissa Driggin, Caroline Der‐Nigoghossian, Walter Ageno, Mohammad Madjid, Yutao Guo, Liang Tang, Yu Hu, Jay Giri, Mary Cushman, I. Quéré, Evangelos Dimakakos, C. Michael Gibson, Giuseppe Lippi, Emmanuel J. Favaloro, Jawed Fareed, Joseph A. Caprini, Alfonso Tafur, John Burton, Dominic P. Francese,

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19

Discussion(0)

Related publications

Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials

Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19

Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19

Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up